Radiotherapy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Radiotherapy uses ionising radiation — high-energy photons, electrons, protons, or radioactive isotopes — to damage the DNA of cancer cells, ultimately inducing cell death. Radiation exploits the differential capacity of malignant cells (which have impaired DNA repair mechanisms) versus normal cells to recover from sub-lethal radiation injury, allowing fractionated treatment to eradicate cancer while preserving normal tissue function.

From the perspective of interventional radiology (IR), radiotherapy is not a single modality but a spectrum of overlapping techniques in which IR physicians play an increasingly central role. Interventional radiologists prepare patients for external beam radiation by inserting fiducial markers for tumour tracking, placing biliary stents to restore liver function before hepatic radiation, and creating vascular access for concurrent systemic therapy. At the same time, IR physicians deliver radiation directly through catheter-based techniques — including brachytherapy catheter implantation and selective internal radiation therapy (SIRT) with yttrium-90 (Y-90) microspheres for unresectable liver tumours.

The classification of radiotherapy modalities relevant to the IR-oncology interface includes: (1) external beam radiotherapy (EBRT) — radiation delivered from outside the body by a linear accelerator or cyclotron; (2) brachytherapy — radiation delivered from implanted radioactive sources within or adjacent to the tumour; and (3) radioembolization (SIRT) — catheter-delivered radioactive microspheres deposited directly in tumour-feeding arteries. Additionally, the comparison between thermal ablation (radiofrequency ablation, RFA; microwave ablation) and stereotactic body radiotherapy (SBRT) for hepatic tumours is a core IR-oncology decision point addressed in detail in this guide.

Radiotherapy — across its multiple modalities — addresses virtually all solid tumour types in both curative and palliative settings. The following represent the highest-volume and most evidence-supported indications.

• Hepatocellular carcinoma (HCC): SIRT (Y-90 radioembolization) for BCLC intermediate-stage disease, portal vein thrombosis, or as a bridge to transplantation. SBRT for localised unresectable HCC where TACE is contraindicated or has failed. Evidence from SARAH and SIRveNIB trials.
• Colorectal liver metastases: SIRT in combination with systemic chemotherapy (FOLFOX/FOLFIRI) for liver-dominant unresectable disease. SIRFLOX trial data (2016) demonstrate improvement in hepatic progression-free survival.
• Early-stage non-small cell lung cancer (NSCLC): SBRT/SABR for medically inoperable T1–T2 N0 NSCLC, achieving 3-year local control rates exceeding 90% (RTOG 0236, CHISEL trial). Considered the standard of care at many thoracic oncology centres globally.
• Prostate cancer: Definitive radiotherapy for localised disease (IMRT ± brachytherapy boost for high-risk disease). HDR brachytherapy combined with EBRT for intermediate- and high-risk prostate cancer.
• Cervical cancer: Concurrent chemoradiation (cisplatin) followed by HDR intracavitary brachytherapy boost is the standard of care for FIGO stage IB2–IVA. LDR brachytherapy also used in resource-limited settings.
• Oligometastatic disease: SBRT per the SABR-COMET randomised trial (Palma et al., 2019, Lancet): ablative SBRT to all metastatic sites improved 5-year OS from 17.7% to 42.3% vs. palliative-intent standard of care in selected oligometastatic patients.
• Bone metastases: Single-fraction EBRT (8 Gy) is as effective as multi-fraction schedules for pain relief (ASTRO bone mets guidelines). Highly conformal SBRT (16–24 Gy, 1–3 fractions) is used for radioresistant histologies (renal cell, melanoma) and spine metastases where cord sparing is critical.

Patient selection for radiotherapy requires assessment of tumour-related, patient-related, and technical factors. Criteria differ substantially by modality.

External beam radiotherapy eligibility: Performance status ECOG 0–2 for curative intent; ECOG 3 may be appropriate for short-course palliative treatment. Adequate organ function (particularly hepatic and renal function for concomitant systemic therapy). Absence of active connective tissue disorders (SLE, scleroderma), which markedly increase radiosensitivity and late toxicity risk. Pregnancy requires multidisciplinary review and gestational age-specific risk assessment.

SBRT-specific eligibility: Tumour number and size constraints apply. Most SBRT protocols treat up to 3–5 lesions (oligometastatic) with individual lesion diameter typically below 6 cm. Proximity to critical structures (central airways, oesophagus, great vessels, bowel) requires careful dosimetric evaluation and may necessitate risk-adapted fractionation. The central zone (within 2 cm of the tracheobronchial tree) carries higher toxicity risk with ultra-hypofractionation (3 fractions), supporting 4–5 fraction protocols for central lung tumours (RTOG 0813 data).

SIRT (Y-90 radioembolization) eligibility: Hepatic-dominant disease with adequate liver reserve. Child-Pugh A liver function is required for most protocols; selected Child-Pugh B patients may be treated at experienced centres. ECOG performance status 0–2. Pre-treatment nuclear medicine scan with technetium-99m macroaggregated albumin (Tc-99m MAA) quantifies hepatopulmonary shunting: lung shunt fraction above 20% (absorbed lung dose exceeding 30 Gy) is a contraindication due to risk of radiation pneumonitis. Portal vein thrombosis is a relative contraindication for TACE but can be managed with SIRT in experienced hands.

Brachytherapy eligibility: Patient anatomy must accommodate the planned applicator or catheter. Contraindications include active infection in the planned implant site, uncorrectable coagulopathy, and insufficient normal tissue between the target and adjacent critical structures (bowel, bladder) for cervical or prostate brachytherapy.

The radiotherapy modalities relevant to the interventional radiology-oncology interface span three main categories, each with distinct technical mechanisms and clinical applications.

External Beam Radiotherapy (EBRT):

• 3D-Conformal Radiation Therapy (3D-CRT): Multiple shaped beams conforming to the target volume, planned on CT simulation data. The standard approach from the 1990s–2000s; still appropriate for many palliative indications and simple geometries. Lower cost and complexity than IMRT.
• IMRT/VMAT: Intensity-modulated delivery with multi-leaf collimator (see dedicated IMRT guide). Standard of care for H&N, prostate, and gynaecological cancers. VMAT (continuous arc delivery) has largely replaced step-and-shoot IMRT for efficiency.
• SBRT/SABR: Stereotactic Body Radiation Therapy delivers high ablative doses per fraction (typically 8–20 Gy per fraction, 3–5 fractions total) with high-precision setup and real-time motion management. Achieves local control rates exceeding 90% for early-stage NSCLC and liver metastases below 3 cm in experienced centres.
• Proton Therapy: Charged particles deposit dose in a Bragg peak at a specified depth, with negligible exit dose. Physical advantage over photons at sites adjacent to critical structures: paediatric tumours, skull-base chordoma, prostate (reduced rectal dose), and H&N. Very high capital cost limits availability to approximately 100 centres globally.

Brachytherapy:

• LDR (Low Dose Rate): Permanent radioactive seed implants (iodine-125 or palladium-103) placed in the prostate gland via transperineal needles under ultrasound guidance. Continuous low-dose-rate irradiation over weeks as the seeds decay. Also used for temporary removable LDR implants in gynecological cancers.
• HDR (High Dose Rate): A high-activity iridium-192 source (approximately 10 Ci) delivered through flexible catheters or applicators (intracavitary for cervical cancer, interstitial for prostate, breast, and soft tissue). Treatment takes minutes per fraction; sources are removed after each fraction. Used for cervical cancer tandem-and-ring/ovoid applicators, prostate implants, endometrial cancer vaginal cuff, and accelerated partial breast irradiation (APBI).
• PDR (Pulsed Dose Rate): Simulates LDR by delivering pulses of radiation every 1–3 hours from an HDR-type source, allowing biological optimisation with greater flexibility than continuous LDR. Common in European centres for cervical cancer and soft tissue sarcoma.

Selective Internal Radiation Therapy (SIRT / Y-90 Radioembolization): An IR-delivered procedure in which resin microspheres (SIR-Spheres, Sirtex Medical) or glass microspheres (TheraSphere, Boston Scientific) loaded with yttrium-90 (a pure beta emitter, half-life 64.1 hours) are infused via a microcatheter selectively positioned in the hepatic arterial branch supplying the tumour. Y-90 decays with a mean tissue penetration of 2.5 mm, delivering absorbed tumour doses of 80–150 Gy while sparing adjacent liver parenchyma. The procedure is performed as a two-stage process: a planning arteriogram with MAA scan (Week 0) to confirm catheter position and measure lung shunt fraction, followed by the therapeutic SIRT procedure (Week 2–4).

Each radiotherapy modality offers distinct clinical benefits, supported by randomised trial data and real-world outcomes registries.

SBRT for early-stage NSCLC: Multiple prospective single-arm studies (RTOG 0236, CHISEL, SPACE) and pooled analyses demonstrate 3-year local control rates of 90–97% for medically inoperable early-stage NSCLC treated with SBRT (54 Gy in 3 fractions for peripheral tumours). These rates are statistically equivalent to surgical resection outcomes in population-adjusted analyses, establishing SBRT as a definitive treatment option for patients unsuitable for surgery.

SABR-COMET (oligometastatic disease): The landmark randomised phase II SABR-COMET trial (Palma et al., Lancet 2019) compared SBRT to all sites of oligometastatic disease (1–5 metastases) versus palliative standard of care. SBRT improved median OS from 28 months to 41 months, and 5-year OS from 17.7% to 42.3%. Phase III validation trials (SABR-COMET-3, SABR-COMET-10) are ongoing. This trial established SBRT as an option to be discussed in multidisciplinary team (MDT) meetings for eligible oligometastatic patients.

Y-90 SIRT for colorectal liver metastases (SIRFLOX trial): The SIRFLOX randomised trial (van Hazel et al., Journal of Clinical Oncology, 2016) enrolled 530 patients with unresectable colorectal liver metastases and randomised them to first-line FOLFOX chemotherapy with or without Y-90 SIRT. The addition of SIRT significantly improved hepatic progression-free survival (20.5 months vs. 12.6 months; HR 0.69, p = 0.002), though overall PFS and OS were not statistically different in the primary analysis. Subsequent pooled analysis of SIRFLOX, FOXFIRE, and FOXFIRE Global (combined n=1,103) showed a trend toward improved OS in patients with right-sided primary tumours.

HDR brachytherapy for cervical cancer: MRI-guided adaptive brachytherapy (EMBRACE I trial, Lancet Oncology 2021) with HDR boost after concurrent chemoradiation demonstrated 5-year local control rates above 90% for stage IB–IIB and 85% for stage III–IVA, with 5-year OS of 65–74%. Image-guided adaptive brachytherapy (IGABT) significantly improves outcomes vs. conventional 2D point-dose brachytherapy.

Radiotherapy side effects are classified by timing (acute vs. late) and by the normal tissue structures within the radiation field.

Acute side effects (during treatment, resolving within 8–12 weeks post-completion): Fatigue (near-universal, resolves post-treatment). Mucositis and dysphagia in H&N radiotherapy — Grade 3 mucositis requiring feeding tube or IV nutrition in 20–30% of patients receiving concurrent chemotherapy. Radiation dermatitis — erythema, dry and moist desquamation in skin-entry regions. Diarrhoea and proctitis in pelvic radiotherapy — managed with dietary modification, antidiarrhoeals, and hydrocortisone foam enemas.

Late side effects (months to years post-treatment): Fibrosis and lymphoedema in the irradiated region. Radiation-induced liver disease (RILD): a severe complication of hepatic irradiation defined by elevated alkaline phosphatase, anicteric ascites, and liver dysfunction within 4 months of radiotherapy. Risk is minimised by keeping mean liver dose below 30–32 Gy (conventional fractionation) and V30 below 40% for SBRT. Radiation pneumonitis: symptomatic in 5–15% of lung radiotherapy patients, correlating with V20 (volume of lung receiving 20 Gy or more) and mean lung dose. Managed with corticosteroids. Secondary malignancy: lifetime absolute risk is 0.1–1.0% for most radiotherapy courses.

SIRT-specific risks: Post-embolization syndrome (nausea, fatigue, low-grade fever) in 20–30% of patients; typically self-limiting over 2 weeks. Radiation gastroduodenitis and radiation cholecystitis if non-target Y-90 deposition occurs (minimised by careful catheter positioning and coil embolization of aberrant vessels). Radiation-induced liver disease (RILD) if lung shunt fraction exceeds 20% or hepatic reserve is insufficient — pre-treatment MAA scan quantification is mandatory. Biliary stricture in 2–5% of patients.

Brachytherapy risks: Catheter or applicator displacement, inadvertent source dwell position error (minimised by independent source position verification). Fistula formation (vesicovaginal, rectovaginal) after cervical cancer brachytherapy in less than 2% of cases with modern IGABT. Urethral stricture and urinary incontinence after prostate brachytherapy (LDR: 1–3% Grade 3 urinary toxicity).

Post-radiotherapy follow-up schedules vary by modality, tumour site, and treatment intent. The following covers the major clinical domains.

External beam radiotherapy follow-up: Clinical review at 4–8 weeks post-completion to assess acute toxicity resolution and document baseline late effects. Imaging response assessment at 8–16 weeks: CT for lung and abdominal targets; PET-CT for H&N cancer (12-week PET recommended by UK NICE guidelines before neck dissection decision); MRI for CNS and prostate. PSA monitoring for prostate cancer (nadir + 2 ng/mL Phoenix definition for biochemical failure). Subsequent clinical visits at 3-month intervals for the first 2 years, then 6-monthly to 5 years.

SBRT follow-up: Imaging at 6 weeks and 3 months post-SBRT, then every 3–6 months for 2 years. Post-SBRT imaging interpretation requires familiarity with radiation-induced lung parenchymal change (consolidation, ground-glass opacity, fibrosis), which can mimic recurrence. PET-CT may be needed to distinguish local recurrence from post-treatment fibrosis, particularly for lung and liver SBRT targets. Pathological confirmation of suspected recurrence is recommended before retreatment.

Y-90 SIRT follow-up: Liver function tests (LFTs), bilirubin, and albumin at 1 month post-SIRT. Cross-sectional imaging (multiphasic CT or MRI) at 6 weeks and 3 months to assess treatment response per modified RECIST (mRECIST) criteria or RECIST 1.1 for liver metastases. PET-CT may demonstrate metabolic response before morphological change. Clinical assessment includes performance status, fatigue, and abdominal symptom review. SIRT may be followed by surgical resection or ablation if adequate hepatic response renders the tumour resectable — a prespecified endpoint in several SIRT trials.

Brachytherapy follow-up: Cervical cancer: clinical examination and colposcopy at 3-month intervals for 2 years post-treatment; MRI pelvis at 3 months to assess primary tumour response. Prostate LDR brachytherapy: PSA every 6 months; post-implant dosimetric CT at Day 30 to confirm adequate seed distribution (D90 — dose covering 90% of the gland — target: 140–160% of prescribed dose for I-125).

Managing treatment response versus progression: The distinction between pseudoprogression (inflammatory or fibrotic treatment response) and true tumour progression is a recurring clinical challenge across all radiotherapy modalities. Multi-parametric imaging (diffusion-weighted MRI, MR spectroscopy, PET-CT) and, where safe, image-guided biopsy of suspected residual or recurrent lesions should be used before committing to salvage treatment.

Radiotherapy costs vary enormously by modality, fractionation schedule, and country. Medical tourism offers significant cost savings for all radiotherapy modalities at internationally accredited centres.

External beam radiotherapy costs: In the US, a curative-intent IMRT/VMAT course (30–35 fractions) for H&N or prostate cancer is priced at USD 35,000–80,000 as listed charges (contracted insurance rates differ substantially). SBRT (5 fractions) is typically USD 20,000–45,000. Conventional 3D-CRT palliative courses (5–10 fractions) are substantially lower. In India at NABH/JCI-accredited centres (Tata Memorial Hospital, Apollo, HCL Healthcare Moolchand), full-course IMRT costs USD 3,500–7,500; SBRT costs USD 3,000–6,000. Thailand (Bumrungrad, Bangkok Hospital): USD 8,000–18,000 for full-course IMRT. Turkey (Acibadem, Medicana): USD 5,000–12,000.

Brachytherapy costs: HDR brachytherapy for cervical cancer in the US: USD 15,000–35,000 for the complete intracavitary course (5 fractions). In India: USD 1,500–3,000. Prostate LDR seed brachytherapy in the US: USD 18,000–30,000. In India and Thailand: USD 2,500–5,000.

Y-90 SIRT costs: SIR-Spheres vial cost is approximately USD 10,000–18,000 per vial in the US market, with total procedure costs including hospital, IR team, and nuclear medicine support reaching USD 25,000–50,000 per treatment session. In India: vial plus procedure costs USD 4,000–8,000. In Thailand and Turkey: USD 7,000–14,000. The planning MAA scan adds USD 1,500–3,000 (US) or USD 300–600 (India).

Proton therapy costs: Due to the high capital cost of proton centres, proton therapy in the US is typically USD 80,000–120,000 for a full course. Outside the US, proton therapy is available at academic centres in Germany, Japan, South Korea, UK, and Czech Republic at costs of USD 25,000–60,000. Insurance coverage for proton therapy varies widely; it is best established for paediatric tumours and select adult indications (chordoma, ocular melanoma).

A key clinical decision in the IR-oncology interface is the selection between thermal ablation (radiofrequency ablation, RFA; microwave ablation, MWA) and SBRT for localised hepatic tumours (HCC and colorectal liver metastases). This decision is guided by lesion size, location, vascular proximity, number of lesions, patient fitness for sedation, and institutional expertise.

Local control equivalence for small lesions: For hepatic tumours below 3 cm in diameter located away from major vascular structures, both RFA and SBRT achieve local control rates of approximately 80–90% at 2 years in retrospective series. A 2018 systematic review and meta-analysis (Murray et al., Radiotherapy and Oncology) found no statistically significant difference in local control or overall survival between RFA and SBRT for hepatic metastases below 3 cm, supporting both as first-line local ablation options in this group.

Advantages of RFA/MWA: Immediate ablation confirmation on post-procedural CT or contrast-enhanced ultrasound. Single-session treatment. Pathological diagnosis of the ablated lesion can be obtained simultaneously. Lower cost per procedure. Better evidence base for HCC (BCLC very early and early stage) within the Milan criteria. Faster recovery with outpatient or overnight stay.

Advantages of SBRT over RFA: The heat-sink effect — heat dissipation into adjacent hepatic blood vessels — reduces RFA efficacy for tumours within 1 cm of vessels above 3 mm diameter. For perivascular lesions, SBRT achieves equivalent local control regardless of vascular proximity. SBRT is the preferred option for patients not suitable for conscious sedation or general anaesthesia, for lesions in difficult percutaneous access locations (dome of the liver, segment I, juxta-diaphragmatic), and for lesions larger than 3 cm where RFA local control rates fall substantially. For multiple lesions (>3), SBRT can treat several targets simultaneously within a single treatment plan while ablation requires sequential separate procedures.

Radioembolization (SIRT) vs. SBRT vs. TACE: For intermediate-stage HCC (BCLC B), TACE (transarterial chemoembolization) remains the first-line locoregional treatment per BCLC and AASLD guidelines. SIRT (Y-90 radioembolization) is preferred over TACE for patients with portal vein thrombosis or dominant disease in one lobe where TACE is contraindicated. SBRT is increasingly used as an alternative to TACE and SIRT for localised HCC at centres with radiation hepatology expertise (dose constraints validated in prospective studies). Head-to-head comparative trial data between these modalities are limited; multidisciplinary tumour board review is essential for case-by-case decision-making.

Systemic therapy integration: Radiotherapy across all modalities is increasingly combined with systemic therapy (immunotherapy, targeted therapy). Abscopal responses — immune-mediated tumour shrinkage at non-irradiated distant sites following SBRT — have been documented in clinical series and are the subject of active investigation in combination with immune checkpoint inhibitors (SBRT + pembrolizumab, SBRT + nivolumab trials). Concurrent sorafenib/lenvatinib with SIRT for HCC and concurrent chemotherapy with liver SBRT for colorectal metastases are active research areas.